#United States #San Diego #Robbins LLP #Vistagen #VTGN

Class Action Alert for Vistagen Therapeutics Investors

In a significant move for investors, Robbins LLP has issued a reminder concerning a class action lawsuit filed against Vistagen Therapeutics, Inc. (NASDAQ: VTGN). This legal action was taken on behalf of individuals who purchased or acquired shares of the biopharmaceutical company between April 1, 2024, and December 16, 2025.

Vistagen Therapeutics is notable for its focus on developing therapies aimed at treating neuropsychiatric and neurological disorders. The recent class action centers around claims that the company's management misled investors about the efficacy of its clinical trial studies, particularly the Phase 3 PALISADE-3 trial concerning their drug, fasedienol.

Allegations Against Vistagen

According to the lawsuit, Vistagen's leadership allegedly disseminated overly optimistic statements regarding the outcomes of its clinical trials while obscuring critical negative information. The complaint details how investors were led to believe that the Phase 3 trial would showcase the effectiveness of fasedienol—only for the results to reveal that the treatment failed to meet its primary endpoint. Specifically, the trial did not demonstrate statistically significant improvement on key metrics, such as the Subjective Units of Distress Scale (SUDS).

On December 17, 2025, following the release of this disappointing trial data, Vistagen’s stock price plummeted from $4.36 to $0.86 per share—a staggering decline of over 80%. This drastic fall signifies the impact of the allegedly misleading statements made during the trial’s duration. Investors who bought in during this period may now face significant financial losses.

The Role of Robbins LLP

Robbins LLP has established itself as a leader in protecting shareholder rights and has been at the forefront of such class action lawsuits since its inception in 2002. The firm emphasizes that all representation is provided on a contingency fee basis, meaning that investors do not need to pay any upfront costs to participate in the legal process.

The law firm urges any shareholders interested in serving as lead plaintiffs to contact them. Being a lead plaintiff allows an individual to represent the other class members in directing the lawsuit's course. However, it is not a requirement to take legal action to be eligible for potential recovery in this case; investors may also opt to remain passive class members.

What You Need to Know

If you believe you are eligible to join this class action or wish to keep updated on developments regarding this lawsuit, consider signing up for notifications through Robbins LLP’s Stock Watch service. The firm pledges to keep shareholders informed about any settlements or developments tied to corporate misconduct.

Contact Information

For more details, investors can reach out to attorney Aaron Dumas, Jr. at Robbins LLP or call their offices at (800) 350-6003. They are dedicated to pursuing transparency and accountability for shareholders, particularly those affected by the fallout from Vistagen’s recent trial outcomes.

Investors should also be mindful that past results in similar cases do not guarantee future outcomes; the legal landscape is ever-changing, and each case is unique.

In conclusion, while the unfortunate circumstances surrounding Vistagen Therapeutics may present a challenging landscape for shareholders, Robbins LLP stands ready to protect and advocate for investor rights. Engaged shareholders are encouraged to stay vigilant and seek guidance to navigate this complex situation effectively.